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Is Misoprostol Cost-effective in the Prevention 
of Nonsteroidal AntHnflammatory Drug-Induced 
Gastropathy in Patients With Chronic Arthritis? 
A Review o f C o n f l i c t i n g E c o n o m i c E v a l u a t i o n s 
G e r o l d S t u c k i , MD; M a g n u s Johannesson, PhD; M a t t h e w H . L i a n g , MD, MPH 
W hether misoprostol, a synthetic Prostaglandin E i analogue, should be routinely prescribed along with nonsteriodal anti-inflammatory drugs (NSAIDS) to pre-vent gastric damage is of great clinical importance and has profound cost im-plications. No consensus exists on whether misoprostol cotherapy results in a 
cost-saving, is cost-effective, or is costly. The different conclusions reached by five economic evalu-
ations of misoprostol can be explained solely by the assumed absolute risk reduction of symptom-
atic ulcer, which was more than seven times greater in the studies that concluded that misoprostol 
was cost-effective than in a study that concluded misoprostol to be costly. Since no study has di-
rectly shown the effectiveness of misoprostol cotherapy in preventing clinically significant ulcer 
disease (ie, hemorrhage and preforation), it is impossible to judge which assumptions are most 
appropriate. The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by mi-
soprostol makes it impossible to conclude whether it is cost-effective in patients with chronic ar-
thritis who use NSAIDS. ( A r c h I n t e r n M e d . 1 9 9 4 ; 1 5 4 : 2 0 2 0 - 2 0 2 5 ) 
Concerns about the increase in health care 
expenditure have stimulated research on 
the costs and benefits of health care in-
terventions. Misoprostol, a synthetic Pros-
taglandin E! analogue, is the only drug 
approved by the Food and Drug Admin-
istration for the prevention of gastric dam-
age from nonsteroidal anti-inflammatory 
drugs (NSAIDs) . Nonsteroidal anti-
inflammatory drugs are used by more than 
8% of the US population, 1 , 2 and NSAID-
associated gastropathy accounts for at least 
2600 deaths and 20 000 hospitalizations 
each year. For rheumatoid arthritis, $200 
million is spent each year for hospitaliza-
tions due to this complication. 3 Whether 
misoprostol should be prescribed rou-
tinely along with NSAIDs is therefore of 
great clinical importance and has pro-
found cost implications. 
The published economic evalua-
tions of misoprostol are interpreted by 
Roth et a l 4 as "the data has consistently 
demonstrated that it is cost-effective to 
coprescribe misoprostol" in high-risk pa-
tients, but others point out limitations of 
the studies, 5 , 6 warn against their uncriti-
cal extrapolation,7 or question the assump-
tions of the evaluations.8 This review evalu-
ates the evidence on the cost-effectiveness 
of routine prescription of misoprostol to 
prevent NSAID-induced gastric ulcers in 
patients with arthritis conditions and out-
lines important areas for future research. 
REVIEW OF PUBLISHED 
ECONOMIC EVALUATIONS 
F r o m t h e D e p a r t m e n t of H e a l t h P o l i c y a n d M a n a g e m e n t , H a r v a r d S c h o o l of P u b l i c 
H e a l t h ( D r s S t u c k i , Johannesson, a n d L i a n g ) , a n d the D e p a r t m e n t s of M e d i c i n e 
( D r L i a n g ) a n d R h e u m a t o l o g y / l m m u n o l o g y ( D r L i a n g ) a n d R o b e r t B . B r i g h a m 
M u l t i p u r p o s e A r t h r i t i s a n d M u s c u l o s k e l e t a l D i s e a s e C e n t e r ( D r s S t u c k i a n d L i a n g ) , 
B r i g h a m a n d W o m e n ' s H o s p i t a l , B o s t o n , M a s s . D r Johannesson is n o w with 
t h e C e n t r e f o r H e a l t h E c o n o m i c s , S t o c k h o l m ( S w e d e n ) S c h o o l of E c o n o m i c s . 
Article Selection 
Economic studies published in the En-
glish language in peer-reviewed Journals 
were identified by a MEDLINE search up 
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to December 1993. Five studies were 
identified. 9- 1 3 
General Comparison of Studies 
Four studies carried out an analy-
sis of the economic benefit of miso-
prostol in patients receiving NSAIDs 
for Osteoarthritis9"12 and one study 
for rheumatoid arthritis.13 An Ameri-
can study9 and a British study 1 0 were 
planned together to allow cross-
national comparisons 1 4; both stud-
ies were funded by the manufac-
turer of misoprostol. The studies by 
Edelson et a l 1 3 and Gabriel et a l 1 2 
were not supported by industry and 
no information on research Sup-
port was made available for the study 
by Jönsson and Haglund. 1 1 
A l l studies used the same ana-
lytic model and compared the costs 
and probability of developing a 
symptomatic gastric ulcer of NSAID 
use with and without routine miso-
prostol (Table 1) therapy. Ofthose 
who had development of a symp-
tomatic gastric ulcer, some would be 
hospitalized. Ofthosehospitalized, 
a certain proportion would require 
an Operation, and the rest would be 
treated medically. 
In each study "symptomatic 
gastric ulcer" and "hospitalization" 
were defined somewhat differ-
ently. Symptomatic gastric ulcer was 
described as "ulcer , " 9 1 1 as "symp-
tomatic ulcer" or "important gas-
trointestinal event," 1 2 or "bleed." 1 3 
Hospitalization was described as 
"hospitalization," 9" 1 1 defined as "se-
rious bleed," 1 2 or as "complicated ul-
cer." 1 3 Gabriel et a l 1 2 were the only 
ones to factor in the costs of miso-
prostol-induced diarrhea, and Edel-
son et a l 1 3 was the only study to in-
clude fatal bleeding. 
Knill-Jones et a l 1 0 performed a 
cost comparison to identify the least 
costly treatment alternative, while 
Hillman and Bloom 9 evaluated the 
price at which the two treatment al-
ternatives would cost the same. The 
remaining three studies used symp-
tomatic ulcer avoided as the mea-
sure of effectiveness and calculated 
the cost to prevent a symptomatic ul-
cer. In addition, Edelson et a l 1 3 cal-
culated the cost per life-year gained. 
No study considered the quality-of-
life impact of NSAID-induced gas-
tropathy or of significant side ef-
fects of misoprostol such as diarrhea. 
A l l studies used the probability 
of an endoscopically detected gas-
tric ulcer developing with misopros-
tol Prophylaxis from a 3-month 
double-blind randomized trial by Gra-
ham et a l 1 5 who studied the effect of 
misoprostol in 420 NSAID recipi-
ents with Osteoarthritis and epigas-
tric pain. Different from the other 
studies, Hi l lman and Bloom 9 and 
Jönsson and Haglund 1 1 did not use the 
published data based on intent to treat 
with a risk of 21.7% having an ulcer 
develop within a 3-month period of 
treatment under NSAID therapy vs 
5.6% under NSAID and misoprostol 
therapy. Instead they used an "assess-
able cohort" approach, assuming a 
risk of 31.3% with NSAIDs vs 2% for 
patients receiving misoprostol co-
therapy. Edelson et a l 1 3 used only the 
relative risk reduction from the study 
by Graham et a l 1 5 but used other data 
to calculate the absolute risk of 
"bleeding" over 1 year. The probabili-
ties of a symptomatic ulcer develop-
ing among patients with endoscopic 
ulcer, compliance with misoprostol 
treatment, rate of hospitalization, and 
surgery were obtained from differ-
ent data sources and varied among the 
studies. 
The two American analyses 9 1 3 
studied 800 |xg of misoprostol daily, 
and the other three studied 400 |xg. 
Edelson et a l 1 3 used a time frame of 
1 year, whereas the other study used 
3 months. Jönsson and Haglund 1 1 in-
cluded both health care costs and in-
direct costs (ie, those attributable to 
loss of p r o d u c t i v i t y at w o r k ) , 
whereas the other studies included 
only health care costs. The assess-
ment of costs varied between the 
studies. 
Table 1. Methodological Characteristics of Economic Evaluations of Misoprostol Prophylaxis 
for NSAID-induced Gastric Ulcer in Patients With Arthritis Conditions* 
Hillman and 
Bloom9 Knill-Jones et al10 
Jönsson and 
Haglund11 Edelson et al13 Gabriel et al12 
Type of analysis 
Perspective 
Effectiveness measure 
Costs included 
Estimation of hospitalization costs 
Price per unit of Service 
Resource utilization 
Estimation of ambulatory costs 
Price per unit of Service 
Resource utilization 
Cost analysis 
Health care System 
Direct costs 
Charges 
Epidemiologie study 
Charges 
Survey of internists 
Cost analysis 
Health care System 
Direct costs 
Accounting costs 
Case review 
Accounting costs 
Survey of general 
practitioners 
Cost-effectiveness 
Societal 
Symptomatic ulcer 
avoided 
Direct and indirect 
costs 
Accounting costs 
of average 
hospitalization 
Accounting costs 
Assumptions by 
the authors 
Cost-effectiveness 
Health care System 
Years of life saved; 
bleed avoided 
Direct costs 
Charges 
Assumptions by 
the authors 
Charges 
Assumptions by 
the authors 
Cost-effectiveness 
Health care System 
Gastrointestinal event 
avoided 
Direct costs 
Charges 
Expert consensus 
Charges 
Expert consensus 
* NSAID indicates nonsteroidal anti-inflammatory drug. 
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Table 2. Risk Estimates Used in Five Economic Evaluations of Misoprostol Prophylaxis 
for NSAID-induced Gastric Ulcer in Patients With Arthritic Conditions* 
Endoscopically Detected Ulcer Rate Symptomatic Ulcer Rate _ , r 
Dose, |ig No Risk No Risk 
Study (Price/df) Misoprostol, % Misoprostol, % Difference, pu Misoprostol, % Misoprostol, % Difference, pu 
Hillman and Bloom9 800 t 31.3 2 29.3 18.8 1.2 17.6 
Knill-Jones et al10 400 ($0.77) 21.7 5.6 16.1 15.2 3.9 11.27* 
Jönsson and Haglund11 400 ($0.93) 31.3 8.2 23.1 18.8 4.9 13.9 
lower risk 400 5 1.31 3.69 3 (0.79 2.21 
(sensitivity analysis) 
Edelson et al13 800 ($2.34) NA NA NA 2.5 ©135 2.3 
(9.4 annual risk||) (0.54 annual risk||) (8.9 annual risk||) 
Gabriel et al12 400 ($1.48) 21.6 5.6 16 14 4.1 9.9* 
* NSAID indicates nonsteroidal anti-inflammatory drug; pu, percentage units; NA, not applicable. 
-\Cost figures, adjusted for average currency exchange rate in year of publication in US dollars, based on 1987,9 1988,10-11 1989,13 and 1990 prices.12 
%The cost of misoprostol was not provided. Breakthrough pricing was evaluated instead. 
^Absolute risk reduction used for the base-case analyses. Conversion of Swedish, British, and Canadian currencies into US dollars based on exchange rates 
for corresponding years.17 
\\Annual risk reversed to 3-month risk (3-month risk=[-0.25*ln(1-annual risk)]). 
RESULTS 
Hillman and Bloom 9 found that the 
cost of the two treatment alterna-
tives would be the same at a price of 
$1.74 per day for misoprostol and 
concluded that misoprostol co-
therapy is cost saving (Table 2). The 
result was sensitive to assumptions 
about rates of silent ulcer and com-
pliance but was less sensitive to rates 
of hospitalization and surgery. 
Knill-Jones et a l 1 0 concluded 
that misoprostol is cost saving. The 
result was sensitive to the silent ul-
cer rate, the compliance rate, and the 
ambulatory costs but not to assump-
tions about the hospitalization rate 
from ulcer disease. 
Jönsson and Haglund 1 1 con-
cluded that misoprostol is cost sav-
ing in patients with Osteoarthritis 
suffering from epigastric pain. In-
clusion of indirect costs only mar-
ginally changed the result. The re-
sult was sensitive to assumptions 
about the price of misoprostol, the 
compliance rate, the cost of ambu-
latory care, the risk of ulcer, and the 
reduction of that risk. It was not sen-
sitive to assumptions about the rates 
of hospitalization and surgery. 
Edelson et a l 1 3 showed that the 
prophylactic administration of miso-
prostol to patients with rheumatoid ar-
thritis resulted in costs of $5300 per 
bleed avoided, $381500 per fatal bleed 
avoided, and $95 600 per life-year 
gained. The cost per life-year gained 
was sensitive to assumptions about 
compliance, the risk of bleeding, the 
risk of serious bleeding, and the risk 
of fatal bleeding. No sensitivity analy-
sis of the cost per bleed avoided was 
presented. Compared with other well-
accepted prevention strategies such as 
pneumococcal vaccination of the el-
derly ($2200peryear of lifesaved, 1989 
prices), both the cost per life-year 
gained and cost per bleed avoided of 
$5300 were judged high. 
Gabriel et a l 1 2 concluded that 
misoprostol is cost-effective and 
costs $625 per symptomatic gastric 
ulcer prevented. The results were 
sensitive to assumptions about the 
ulcer complication rate (hospital-
ization), the cost of ambulatory treat-
ment, and the cost of misoprostol. 
C O M M E N T 
Reasons for the 
Different Conclusions 
The results of five economic evalu-
ations of misoprostol Prophylaxis for 
NSAID-induced gastropathy ränge 
from cost saving 9 1 1 or cost-effec-
tive 1 2 to excessively costly. 1 3 These 
different conclusions could result 
from the use of different decision 
models, different probabilities, dif-
ferent target populations and treat-
ment periods, and different cost es-
timates or computational errors. 
A criitical examination of the 
studies shows that the apparent dif-
ferences i n the results are not from 
differences in the decision-analytic 
model or computational errors but 
from the assumptions about the 
magnitude of the misoprostol ef-
fect. Four studies are based exclu-
sively on the results of one random-
ized controlled trial evaluating the 
effect of misoprostol on the devel-
opment of endoscopically detected 
ulcer in patients with Osteoarthri-
t is . 1 5 Edelson et a l 1 3 combined the 
relative risk from this trial with an 
absolute lulcer risk obtained from 
epidemiologic studies. Since to our 
knowledge no study has directly 
shown the effectiveness of misopros-
tol cotherapy in preventing clini-
cally significant ulcer disease such 
as hemorrhage and Perforation, it is 
not possible to judge which assump-
tions are rnost appropriate. In Table 
2, the absolute risk reduction of 
Edelson et a l 1 3 is converted to a 
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Compliance-Adjusted Rate 
I : " 
No 
Misoprostol, % Misoprostol, % 
11.3 0.72 
NA NA 
14.8 3.4 
2.37 0.62 
1.5 0.08 
NA NA 
Risk 
Difference, pu Results* 
10.58* Cost saving if drug costs 
<$1.74/d 
NA Cost saving 
10.95* Cost saving 
1.75 Net costs per symptomatic 
ulcer avoided ($3754) 
1.4* Net costs per bleed 
avoided ($5300) 
NA Net costs per gastrointestinal 
event avoided ($625) 
3-month risk figure1 6 to allow a com-
parison with the other studies. Af-
ter adjustment for silent ulcer rate 
and compliance, the absolute risk re-
duction of Edelson et a l 1 3 is 1.4 per-
centage units (pu) whereas the other 
four studies use an absolute risk re-
duction of approximately 10 pu. The 
critical impact of this difference can 
be demonstrated comparing the re-
sult of Edelson et a l 1 3 with that of 
Jönsson and Haglund. 1 1 When the 
latter authors varied the absolute risk 
reduction in a sensitivity analysis us-
ing approximately 1.75 pu instead 
of 10.95 pu, the net costs per symp-
tomatic ulcer avoided were esti-
mated to be $3754 (Table 2). This 
cost-effectiveness ratio is of similar 
magnitude to the $5300 reported by 
Edelson et a l , 1 3 and both studies 
would have reached the conclu-
sion that misoprostol cotherapy is a 
costly strategy for preventing NSAID 
gastropathy. 
Differences in hospitalization 
rates used probably explain why 
Gabriel et a l 1 2 showed net costs 
whereas Jönsson and Haglund 1 1 and 
Knill-Jones et a l 1 0 documented cost 
savings even though the same drug 
dose and similar absolute ulcer risk 
reduction were used. Knill-Jones et 
a l 1 0 used a hospitalization rate of 
5.6% and Jönsson and Haglund 1 1 
used a figure of 8.6% among pa-
tients w i t h symptomatic ulcer, 
whereas the 0.3% reported by Gab-
riel et a l 1 2 for patients younger than 
60 years of age is considerably lower. 
Using sensitivity analysis, Gabriel et 
al12showed that a hospitalization rate 
of 1.2% among NSAID users (a fig-
ure corresponding to a conditional 
probability of hospitalization among 
ulcer users of 8.6%) would result in 
cost savings. This risk is, in fact, 
equivalent to the probability (8.6%) 
assumed by Jönsson and Haglund 1 1 
and by Hillman and Bloom. 9 
H i l l m a n and B loom 9 exam-
ined 800 fxg of misoprostol daily 
rather than 400 |xg in the other three 
studies 1 0" 1 2 and calculated an abso-
lute risk reduction of approxi-
mately 10.6 pu—a value similar to 
the approximately 11 pu used by 
Knill-Jones et a l 1 0 and Jönsson and 
Haglund. 1 1 The similar absolute risk 
reduction computed despite differ-
ences in the absolute risk for differ-
ent doses of misoprostol results from 
different Interpretation of the Gra-
ham et a l 1 5 c l in ica l trial. K n i l l -
Jones et a l 1 0 and Gabriel et a l 1 2 used 
intent-to-treat data, whereas H i l l -
man and Bloom 9 and Jönsson and 
Haglund 1 1 included only patients 
who completed misoprostol therapy 
(the assessable cohort). The latter 
yields a 31.3% risk of endoscopi-
cally detected ulcer without miso-
prostol and a 2% risk with 800 \Lg 
of misoprostol daily, as compared 
with 21.7% and 1.4% actually re-
ported by Graham et a l . 1 5 When the 
studies of Hillman and Bloom 9 and 
Jönsson and H a g l u n d 1 1 are ad-
justed for compliance (assuming 
rates of 60% and 79%, respec-
tively), similar absolute risk reduc-
tion results. 
Different study conclusions 
may also be related to assumptions 
about the costs of misoprostol and 
ambulatory care. Estimates of am-
bulatory costs were similar and be-
tween $733 and $986 in four stud-
i e s 9 1 1 1 2 (figures based on the average 
currency exchange rate in the year 
of analysis).17 Ambulatory costs were 
lower in Britain ($561 1 0), but since 
misoprostol costs were also lowest 
in Britain, this had no impact on the 
result. For the other studies, the dif-
ferent costs of misoprostol were 
mainly due to the different doses 
used. The effect of the higher dose 
in the study of Edelson et a l 1 3 was 
small compared with the effect of as-
sumptions about absolute risk re-
duction. 
Critique of the Studies 
Endoscopically observed gastric 
damage has been questioned as a 
clinically meaningful end point since 
progression to significant bleeding 
and frank gastric ulcer is not clear. 
The endoscopic ulcer risk from 
NSAID therapy varies between 5% 
and 25%. 1 8 The rate of 21.7% ob-
served in the study of Graham et a l 1 5 
and used by four studies 9" 1 2 is likely 
to be high. In recent studies by Ver-
dickt et a l 1 9 and Graham et a l 2 0 on 
cotherapy of misoprostol with dif-
ferent NSAIDs, the absolute endo-
scopic gastric ulcer risk was 4% 1 9 and 
9% 2 0 in the placebo group, which is 
considerably smaller than the one 
used in the economic evaluations. 
Using the correspondingly smaller 
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absolute risk reduction would have 
led to net costs for misoprostol in all 
studies. 
The absolute gastric ulcer risk 
is critical to the result and differs be-
tween patient populations. Pa-
tients with Osteoarthritis (the focus 
of four studies) are more likely to 
have development of an NSAID-
induced gastropathy since they are 
generally elderly, a group shown to 
be at increased risk. 2 1 Patients with 
rheumatoid arthritis (the object of 
the study of Edelson et al 1 3), how-
ever, may be at increased risk ow-
ing to their frequent Steroid use in 
combination with NSAID therapy.21 
However, whether the two diseases 
themselves are associated with a dif-
ferent ulcer risk is unknown. Of 
more importance may be the NSAID 
utilization pattern. The cumulative 
risk in long-term for rheumatoid ar-
thritis is likely to be higher than in 
short-term or intermittent users as 
in Osteoarthritis. However, the cu-
mulative effect from misoprostol 
Prophylaxis is also dependent on the 
hazard function of gastropathy de-
veloping under NSAID therapy. Less 
cumulat ive effectiveness and a 
higher cost-effectiveness ratio are ex-
pected i f the r i s k of N S A I D -
induced gastropathy decreases over 
time. A decreasing risk over time has 
been suggested by epidemiologic 
studies 2 2 2 and corresponds to the 
biologic phenomenon of "gastric ad-
aptation." 2 3 Alternatively, the de-
creasing risk may be explained by 
subjects intolerant of NSAIDs stop-
ping therapy early after starting 
NSAID therapy; the hazard func-
tion itself may well be stable over 
time. The last possibility is consis-
tent with a constant hospitaliza-
tion rate observed over years among 
patients with rheumatoid arthri-
tis.3 Better epidemiologic data on the 
hazard function, the risk of first us-
ers vs repeated users, and the abso-
lute risk for patients with different 
conditions are therefore for more 
precise estimates and a more accu-
rate economic evaluation. Finally, 
the scenarios studied should be clini-
cally relevant and the four studies 
that model decision-making for Os-
teoarthritis beg the question alto-
gether of whether NSAIDs are nec-
essary and for how long. Recent data 
show that analgesic therapy wi th 
acetaminophen is as effective as 
N S A I D s . 2 4 2 5 Even in the presence of 
an inflammatory component, pro-
longed dosing of NSAIDs may not 
be necessary. 
The value judgment of whether 
the cost of Prophylaxis per symp-
tomatic ulcer prevented is accept-
able cannot be deduced unless we 
know how much society is Willing 
to spend to avoid an ulcer. The com-
parison of costs with "symptomatic 
ulcer prevented" used in the pub-
lished economic evaluations is dif-
ficult to interpret since the bürden 
of ulcer disease remains unquanti-
fied and important effects such as ad-
verse events and death are omitted. 
It would therefore be preferable to 
express the effects in terms of qual-
ity-adjusted life-years, 2 6 healthy-
years equivalents,27 or willingness to 
pay. 2 8 Expressing the effects in terms 
of Utilities or willingness to pay ag-
gregates important health effects, in-
cluding suffering from gastropa-
thy, death, and adverse treatment 
effects into one Single, common unit 
and permits meaningful compari-
sons with other health-care pro-
grams. 
The most important compo-
nent of cost that must be investi-
gated further is ambulatory care, 
since the results of all five studies 
were sensitive with respect to these 
costs. It is critical to obtain actual 
ambulatory costs on the basis of ob-
served utilization. 
C O N C L U S I O N 
Concern about the c l inical rel-
evance of modeling 3-month NSAID 
usage in Osteoarthritis and uncer-
tainty about key assumptions i n the 
studies published to date make it 
hazardous to draw conclusions 
about the cost-effectiveness of pro-
phylactic misoprostol in NSAID us-
ers with arthritic conditions. Rou-
tine prophylactic use of misoprostol, 
a practice promulgated with the mar-
keting of fixed combinations of mi-
soprostol with NSAIDs available in 
Europe and Canada, is likely to be 
excessively costly for many pa-
tients at low risk of gastropathy. The 
evidence of cost-effectiveness is not 
strengthened by the publication of 
more studies based on the same un-
certain assumptions. Instead, bet-
ter effectiveness data on clinically 
relevant outcomes and evaluation 
methods that integrate all relevant 
health effects into one common, in-
terpretable unit are needed before 
misoprostol is recommended on 
cost-effectiveness grounds. 
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